Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.43
$0.169913.48%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.26% | 10.56% | -4.23% | 19.81% | 14.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.26% | 10.56% | -4.23% | 19.81% | 14.51% |
| Cost of Revenue | 0.74% | -0.64% | -10.95% | 17.74% | 12.96% |
| Gross Profit | 14.71% | 17.61% | 0.86% | 21.10% | 15.53% |
| SG&A Expenses | 11.34% | 14.67% | 0.94% | 17.76% | 17.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 87.10% | 95.92% | -7.45% | 125.81% | -3,698.81% |
| Total Operating Expenses | 7.61% | 8.93% | -5.60% | 19.22% | 13.79% |
| Operating Income | 15.88% | 17.37% | 1.75% | 22.25% | 17.50% |
| Income Before Tax | 50.48% | 15.82% | -77.53% | 5.90% | 6.13% |
| Income Tax Expenses | 37.58% | 19.67% | -33.92% | -1.93% | -14.60% |
| Earnings from Continuing Operations | 55.35% | 14.39% | -127.91% | 10.12% | 16.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.35% | 14.39% | -127.91% | 10.12% | 16.83% |
| EBIT | 15.88% | 17.37% | 1.75% | 22.25% | 17.50% |
| EBITDA | 14.87% | 19.49% | -0.13% | 22.35% | 17.77% |
| EPS Basic | 60.08% | 16.16% | -129.37% | 15.66% | 18.54% |
| Normalized Basic EPS | 55.02% | 17.65% | -76.92% | 11.05% | 7.73% |
| EPS Diluted | 60.08% | 16.16% | -129.37% | 15.66% | 18.54% |
| Normalized Diluted EPS | 55.02% | 17.65% | -76.92% | 11.05% | 7.73% |
| Average Basic Shares Outstanding | -2.88% | -1.39% | -5.10% | -4.78% | -1.67% |
| Average Diluted Shares Outstanding | -2.88% | -1.39% | -5.10% | -4.78% | -1.67% |
| Dividend Per Share | -- | 12.38% | -42.27% | -- | -- |
| Payout Ratio | -0.29% | -- | -3.01% | -- | -0.52% |
